B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
HRMY
Harmony BiosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$47.36
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.2
Score
AI commentary
Primary-source Q2 disclosures are positive on record WAKIX revenue, reiterated guidance, and BP-205 progress [#SEC-8K-2026-08-04]. Stored earnings context also reports a Q2 EPS and revenue beat, but verified post-print analyst revisions, target changes, options skew, short interest, employee sentiment, and social coverage are unavailable. The recent share-price trend was positive in secondary coverage, but attribution should be treated cautiously.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventBP-205 clinical development milestonesHigh impact
Initial Phase 1 single-ascending-dose data showed favorable pharmacokinetic and safety/tolerability profiles. Multiple-ascending-dose data are expected in Q4 2026, followed by further development milestones in 2027 [#SEC-8K-2026-08-04].
2026-12-31catalystWAKIX commercial execution and 2026 guidance deliveryMedium impact
Q2 WAKIX net revenue reached $261.3 million, up 30% year over year, with average patients increasing to approximately 8,950. Management reiterated 2026 net revenue guidance of $1.0 billion to $1.04 billion [#SEC-8K-2026-08-04].
2027-04-01catalystPitolisant lifecycle-extension milestonesHigh impact
The pitolisant gastro-resistant formulation NDA was accepted with a target PDUFA date of April 1, 2027, while pitolisant HD remains on track for Phase 3 topline data in 2027 [#SEC-8K-2026-08-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology